Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

FDA Flags “Testing Into Compliance”; Auriga Warning Letter Exposes Quality Unit Failures

Auriga Research Pvt. Ltd. has received an FDA Warning Letter after a February 2026 inspection of its contract testing laboratory in Bengaluru, India. FDA cited significant CGMP violations involving incomplete laboratory records, weak Quality Unit oversight, and OOS investigations based
  • News
FDA Flags “Testing Into Compliance”; Auriga Warning Letter Exposes Quality Unit Failures

FDA Warning Letter Flags OOS Averaging; Confirmed OOS Still Led to Batch Release

The U.S. Food and Drug Administration (FDA) has issued a Warning Letter to ABS Corporation, a veterinary drug manufacturer in Omaha, Nebraska, after a January 2026 inspection identified significant CGMP violations involving OOS investigations, incoming component testing, and process validation.
  • News
FDA Warning Letter Flags OOS Averaging; Confirmed OOS Still Led to Batch Release

FDA Finds Gaps in Genzyme’s Data Integrity Program; Warning Letter Cites Discarded Review Records

The FDA has issued a warning letter to Sanofi’s Genzyme manufacturing facility in Waterford, Ireland, after identifying significant weaknesses in Data Integrity and quality management during an inspection. The agency found deficiencies in laboratory record reviews, traceability, and deviation handling
  • News
FDA Finds Gaps in Genzyme's Data Integrity Program; Warning Letter Cites Discarded Review Records

Novo Nordisk Faces FDA Warning Letter — Missed Death Reports Expose Pharmacovigilance Failure

FDA issues warning letter to Novo Nordisk over missing safety reports and death data gaps in pharmacovigilance systems, citing serious compliance breakdowns and increasing inspection risk.
  • News
Pharmacovigilance specialist analyzing drug safety data and regulatory reports in a digital pharmaceutical monitoring system with AI-driven risk visualization dashboards.